Suzanne Ildstad
American physician and medical researcher
From Wikipedia, the free encyclopedia
Suzanne Tollerud Ildstad (born May 20, 1952, in Hennepin County, Minnesota) is an American physician and medical researcher.[1] She is the Chief Scientific Officer and founding CEO of Talaris Therapeutics (her discovery of tolerogenic graft facilitating cells led to the formation of the company).[2] She also serves the board of directors. She is also the Jewish Hospital Distinguished Professor of Transplantation Research, Director of the Institute for Cellular Therapeutics,[3] Professor in the Department of Surgery with associate appointments in the Departments of Physiology & Biophysics and Microbiology & Immunology at the University of Louisville School of Medicine.[4]
.jpg)
May 20, 1952
Suzanne Tollerud Ildstad | |
|---|---|
| |
| Born | Suzanne Ildstad May 20, 1952 |
| Alma mater | Mayo Clinic Medical School |
| Occupations | Physician, medical researcher |
| Known for | Founding CEO of Talaris Therapeutics |
Life
After earning her medical degree at Mayo Clinic Medical School, Ildstad did her surgical residency at Massachusetts General Hospital, an immunology fellowship at the National Institutes of Health, and a pediatric surgery/transplant fellowship at Cincinnati Children's Hospital.[2]
Ildstad was elected to the National Academy of Medicine in 1997 and in 2014 was made a fellow of the National Academy of Inventors.[5][6]
Ildstad is a named inventor or co-inventor on more than 100 patents.[2]
She changed her middle name to "Tollerud" upon her marriage to David J. Tollerud, M.D. They have a son and a daughter.[7]
